(P129) Electronic Brachytherapy for Nonmelanomatous Skin Cancer: Report of First 565 Lesions

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

Electronic brachytherapy for skin cancer is now available without the need for room shielding. Advances in radiobiology and radiotechnology permit the treatment course to be given in eight fractions over 4 weeks. This report describes the experience with our first 565 treated lesions.

Stephen W. Doggett, MD; Transdermal Radiation Associates

Purpose: Electronic brachytherapy for skin cancer is now available without the need for room shielding. Advances in radiobiology and radiotechnology permit the treatment course to be given in eight fractions over 4 weeks. This report describes the experience with our first 565 treated lesions.

Materials and Methods: A miniaturized 50-keV x-ray tube and delivery system (Xoft Inc, Fremont, California) are FDA-approved for nonmelanotic skin cancers (NMS). The device is operated in a standard unshielded examination room.

Results: Fifteen months following introduction of the system, a total of 565 NMS have been treated. There have been two recurrences, and cosmesis has been excellent.

Conclusions: Radiation therapy for NMS can now be given in an office setting as an alternative to Mohs surgery. Results are comparable to or better than those of surgery. Patients are pleased with the outcome and convenience of the short course of therapy given in the office.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Related Content